Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAOT46
|
|||
| Drug Name |
LY2787106
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-10: D50-D64] | Phase 1 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepcidin (HAMP) | Target Info | Inhibitor | [2] |
| WikiPathways | Iron metabolism in placenta | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01340976) A Phase 1 Study of LY2787106 in Cancer and Anemia. U.S. National Institutes of Health. | |||
| REF 2 | A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.